β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome
Name
Mellios-2014-beta 2-Adrenergic re.pdf
Size
1.04 MB
Format
Adobe PDF
Checksum (MD5)
9b6eae2328848190355fd4bac73c0079
Author(s)
Mellios, Nikolaos
Woodson, Jonathan
Garcia, Rodrigo
Crawford, Benjamin
Sharma, Jitendra
Sheridan, Steven
Sur, Mriganka
Haggarty, Stephen J.
Date Issued
June 2014
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
National Academy of Sciences (U.S.)
Citation
Mellios, Nikolaos, Jonathan Woodson, Rodrigo I. Garcia, Benjamin Crawford, Jitendra Sharma, Steven D. Sheridan, Stephen J. Haggarty, and Mriganka Sur. “ β2-Adrenergic Receptor Agonist Ameliorates Phenotypes and Corrects microRNA-Mediated IGF1 Deficits in a Mouse Model of Rett Syndrome.” Proceedings of the National Academy of Sciences 111, no. 27 (June 23, 2014): 9947–9952.
Version
Final published version
Abstract
Rett syndrome is a severe childhood onset neurodevelopmental disorder caused by mutations in methyl-CpG–binding protein 2 (MECP2), with known disturbances in catecholamine synthesis. Here, we show that treatment with the β2-adrenergic receptor agonist clenbuterol increases survival, rescues abnormalities in respiratory function and social recognition, and improves motor coordination in young male Mecp2-null (Mecp2−/y) mice. Importantly, we demonstrate that short-term treatment with clenbuterol in older symptomatic female heterozygous (Mecp2−/+) mice rescues respiratory, cognitive, and motor coordination deficits, and induces an anxiolytic effect. In addition, we reveal abnormalities in a microRNA-mediated pathway, downstream of brain-derived neurotrophic factor that affects insulin-like growth factor 1 (IGF1) expression in Mecp2−/y mice, and show that treatment with clenbuterol restores the observed molecular alterations. Finally, cotreatment with clenbuterol and recombinant human IGF1 results in additional increases in survival in male null mice. Collectively, our data support a role for IGF1 and other growth factor deficits as an underlying mechanism of Rett syndrome and introduce β2-adrenergic receptor agonists as potential therapeutic agents for the treatment of the disorder.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Massachusetts Institute of Technology. Research Laboratory of Electronics
Picower Institute for Learning and Memory
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1309426111
